A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas-Reference-Cited by-同舟云学术

A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas

Published:2023-01-25 Issue:3 Volume:7 Page:314-316
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Rindone Giovanni¹²^ORCID,Aroldi Andrea¹²,Bossi Elisa¹²,Verga Luisa¹,Zambrotta Giovanni¹²^ORCID,Tarantino Sara¹²,Piazza Rocco¹²^ORCID,Mussolin Lara³,Chiarle Roberto⁴⁵^ORCID,Gambacorti-Passerini Carlo¹²^ORCID

Affiliation:

1. 1Hematology Division, San Gerardo Hospital, Monza, Italy

2. 2Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy

3. 3Department of Woman’s and Child’s Health, University of Padova, Padova, Italy

4. 4Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy

5. 5Department of Pathology, Boston Children’s Hospital and Harvard Medical School, Boston, MA

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/7/3/314/2033365/blooda_adv-2022-007538-main.pdf

Reference14 articles.

1. Anaplastic large cell lymphoma: contemporary concepts and optimal management;Shustov;Cancer Treat Res,2019

2. NPM-ALK: a driver of lymphoma pathogenesis and a therapeutic target;Andraos;Cancers (Basel),2021

3. ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion;Chang;Mod Pathol,2019

4. ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma;De Paepe;Blood,2003

5. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases;Onciu;Blood,2003

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diverse and reprogrammable mechanisms of malignant cell transformation in lymphocytes: pathogenetic insights and translational implications;Frontiers in Oncology;2024-04-03

2. Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL;Frontiers in Immunology;2024-02-05

3. Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review;Cancers;2023-10-11

4. Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma;Science Translational Medicine;2023-06-28

5. How molecular advances may improve the diagnosis and management of PTCL patients;Frontiers in Oncology;2023-06-23